Metabasis to Host Inaugural Investor Research & Development Meeting
Posted on: Tuesday, 12 December 2006, 09:00 CST
SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Metabasis Therapeutics , announced today that the Company will host its first Investor Research & Development Meeting on Thursday, December 14, 2006 at the Warwick New York Hotel in New York, NY. The event is scheduled to run from approximately 8:00 a.m. - 11:00 a.m. Eastern Time. Dr. Paul Laikind, president and CEO, is expected to provide a general business overview and Dr. Mark Erion, executive vice president of research and development and CSO, is expected to present on the Company's product candidates in clinical and pre-clinical development.
To access the live audio broadcast and the subsequent archived audio recording of the presentation, please log onto the Company's website at http://www.mbasis.com/ under the "Investors" section. Please connect to Metabasis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. The audio recording will be archived there for 30 days following the live presentation.
About Metabasis (http://www.mbasis.com)/
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis Therapeutics
CONTACT: Constance Bienfait, Vice President of Investor Relations &Corporate Communications of Metabasis Therapeutics, Inc., +1-858-622-5575
Web site: http://www.mbasis.com/
Source: PRNewswire-FirstCall
Related Articles
- Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
- Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development
- DiaKine Therapeutics' Lead Compound in Phase 2 Clinical Trial
- MaxCyte to Present Scalable Clinical and Commercial Manufacturing Technology for Cell-Based and Viral-Based Vaccines
- Alnylam Presents Pre-Clinical Data From Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy (PML) Programs at RNAi Keystone Symposium
- Gene Logic and Solvay Pharmaceuticals Enter Agreement to Discover New Development Paths for Multiple Clinical Drug Candidates
- Celldex Therapeutics Announces Poster Presentations of Lead Product Candidates at ASCO Annual Meeting
- Alnylam and Collaborators Present Pre-Clinical Data for RNAi Therapeutics for the Treatment of Respiratory Diseases Including Pandemic Influenza; Results Include Data on Anti-Viral Activity of RNAi Therapeutics Toward H5N1 Virus
- Gene Logic and Roche Enter Collaboration to Discover New Development Paths for Multiple Clinical Drug Candidates
- Lead Investigator to Present Positive Clinical Study Results for Chelsea Therapeutics' Lead Compound CH-1504 at ACR 2005 Annual Scientific Meeting
 |
 |
User Comments (0)
RSS Feeds